Contribute Try STAT+ Today

As the Biden administration assumes leadership in Washington and former President Donald Trump’s most-favored nation ruling has been halted by a federal judge, drug price controls don’t feel imminent.

Though this should provide some relief to the R&D-based biopharmaceutical industry, the relief may be short-lived.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I hope the author had compared each healthcare system. In USA with the mutually subsidized healthcare system no one even the author knows any pricing at any point in the supply chain. Then we have BIG GORILLA (PBM and insurance companies) who don’t want to change the current system as their golden goose will disappear. Till nationalized nothing will change. Politicians will make sure that nothing is altered.

    Has the author reviewed the workings of the current system? He should. Pundits have written, are writing and will be writing in 2050. No change will happen.

Comments are closed.